Overview

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.
Treatments:
toripalimab